The original vitamin K2 The best documented, commercially available natural vitamin K2 Guaranteed activity, stability and safety Clinical substantiation International patents granted and pending
NattoPharma 2013
Finans
Kapitalisering Styrking av kapitalsituasjonen: 1. Gjennomført emisjon på NOK 10,7 mill. til kurs NOK 20,- 2. Innbetaling av warrants i juli tilfører ytterligere NOK 11,9 mill. 3. Forventet cash posisjon 31. juli er NOK 30 mill. 4. Forventet egenkapital NOK 43 mill ex. Q2 res.
Helsekost og Pharma Kostnadssplitt Fra 2. kvartal i år vil selskapet splitte inntekter og kostnader i en avd. for helsekost og en avd. for pharma hvor selskapets pharmasatsing etter hvert vil bli rapportert gjennom VitaSynth (forutsatt ett oppkjøp som gir NattoPharma 100 % eierskap i dette selskapet) Det er ønskelig å vise resultatutviklingen innen disse to strategiske satsingsområdene hver for seg i 2013 som en segmentoppstilling
Offentlige tilskudd/støtteordninger Skattefunn Utvide selskapets satsing innen FoU - hvor støtteordningen Skattefunn vil være en viktig kilde til finansiering og hvor Universitetet i Maastricht i Nederland vil være en viktig samarbeidspartner EU Pharmastrategien vil være basert på at selskapet finner gode finansielle støtteordninger gjennom EU-midler samt lokalefinansieringsordninger.
Organization and operation
NattoPharma Organization Frank Bjordal Board Member The Board of Directors Frode Bohan Chairman of the Board Katarzyna Maresz Board Member Frode Bohan is a full time Executive Chairman. Katarzyna Maresz is managing parts of the company s R&D Hogne Vik CEO Eric Anderson SVP Global Sales and Marketing Piotr Sierdziński Project Leader Erik Tjørstad CFO Käthe Bleken European Sales Camilla Lindberg Marketing Manager Thomas Hillyer US Customer Support Małgorzata Włodarczyk Sales Department Director Head Office US Sales team Functional Foods team NattoPharma has agreements with distribution partners in the most important markets selling directly to major customers in their market.
Local Representation North and South America Europe, Russia, Middle East and Africa 2014 Asia and Oceania
Functional foods team in Central Europe Functional foods: Launch of Strong Milk, diary company Seven new products with a big milk protein company, launched in May at Vitafoods Chocolate milk, diary company A Large international diary company, soon to be signed an agreement
NattoPharma Market Focus NattoPharma has identified three major market segments for MenaQ7 Current focus Future area Supplement Functional Foods Pharmaceutical
NattoPharma Market Focus Medium Term Focus on Dietary Supplements & Functional Foods Sell MenaQ7 as an ingredient into existing global leading brands in the following market segments: Pharmacy Volume of vitamin K2 Dietary supplement Functional Foods Time
180 Global sales of supplements and Functional Foods Sales in billion USD 160 140 120 100 80 60 40 20 00 57 62 68 73 79 35 38 41 43 46 49 52 56 59 62 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Supplements 85 90 Functional Foods Supplements include relevant sub segemnts such as Vitamins and Minerals, Sports and Specialty Supplements 95 97 102 Source: NBJ s Global Supplement & Nutrition Industry Report 2012
The potential in Functional Foods Global sales of breakfast cereals is estimated to be around 30 bill USD per year Cheese consumption in Western Countries averaged around 10,9 kg per person in 2005 Yearly consumption of liquid milk in the EU average more than 100 liters per person By 2015, global yogurt comsumption is expected to reach 20,6 mill tons representing around 67 bill USD in sales
Marketing
Blogs Focus on online activities Banner ads
Thank you for your time and attention!